Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML
arcticnovartis
- Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1
- Clinically relevant 15.2% higher MMR rate achieved with Scemblix vs. 2G TKIs1